Copy/Paste the key inputs from the product brochure, per guidance from Solutions.

Osteoarthritic (OA) pain is a prevalent subtype of chronic pain, affecting more than 43 million individuals in the EU5. OA pain treatment decisions are driven primarily by rheumatologists, orthopedics (in Germany), and pain specialists while general practitioners play an important role in long-term disease management. A variety of analgesic drug classes, containing both branded and generic agents, as well as surgical interventions are available for the treatment of OA pain. However, due to variability in patient response and disease progression, patients struggle to attain adequate analgesia without the introduction of intrusive side effects (e.g., cardiovascular events, tolerance, dependence), which also leads to high rates of polypharmacy. Currently, treatment revolves around the use of generic nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid-containing products, but physicians indicate the need for efficacious drugs that are not associated with safety and tolerability issues.

Questions Answered

  • How is OA pain treated in the EU5, and what differences in treatment exist among countries and between physician specialties?
  • What factors drive switching between select analgesics?
  • How does the availability of surgical intervention as a viable treatment for OA pain impact prescribing of pharmacological analgesics?
  • How does patient risk for abuse/history of abuse influence physicians’ prescribing of opioid analgesics for OA pain?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.

Markets covered: France, Germany, Italy, Spain, United Kingdom

Primary research: Survey of 25 pain specialists and 25 rheumatologists in each EU5 country

Key companies: Mundipharma, Grünenthal, Sanofi, Janssen, Pfizer, Novartis

Key drugs covered: Buprenorphine patch, diclofenac topical gel, etoricoxib, hyaluronic acid injection, Palexia Retard/SR, Vimovo

Key insights provided:

  • Factors influencing disease management and treatment decisions.
  • Drivers and constraints of treatment selection.
  • Physician-reported treatment practices and brand-level patient shares.
  • Rationale for changes in treatment approach.
  • Physician insight on persistency and compliance.
  • Physician-reported recent/anticipated changes in brand usage or treatment approach.

Table of contents

  • Osteoarthritic Pain - Current Treatment - Detailed, Expanded Analysis (EU5)

Author(s): Joyce Spadafora, ALM

Joyce is a business insights analyst in Decision Resources Group’s central nervous systems and ophthalmology division, where she provides expert insight into commercial aspects of drug development and market sizing across psychiatric and pain indications. She has worked extensively in DRG’s schizophrenia and chronic pain content.

Prior to joining DRG, Joyce spent several years in the biotech industry focused in research and development and in biotech consulting. Her project experience covered indications including psychiatry, pain, infectious diseases, respiratory, and ophthalmology. Beyond my therapeutic and industry knowledge, she holds a Masters in Extension Studies in Psychology from Harvard University and a B.S in Mechanical Engineering with Biology from the Massachusetts Institute of Technology.


Related Reports

Osteoarthritic Pain - Landscape & Forecast - Disease Landscape & Forecast

OA pain is the second largest segment of the overall chronic pain market, affecting more than 90 million patients in the G7. The OA

View Details